^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    cRAF inhibitor

    Related drugs:
    3d
    A Study of Avutometinib for People With Solid Tumor Cancers (clinicaltrials.gov)
    P1, N=3, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=23 --> 3
    Enrollment closed • Enrollment change
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • NF1 (Neurofibromin 1) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11)
    |
    Avmapki (avutometinib) • Fakzynja (defactinib)
    6d
    Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory (clinicaltrials.gov)
    P2, N=7, Terminated, Northwestern University | Trial completion date: Jul 2030 --> Apr 2026 | Active, not recruiting --> Terminated | Trial primary completion date: May 2026 --> Oct 2025; The study was closed due to accrual.
    Trial completion date • Trial termination • Trial primary completion date
    |
    BRAF V600E • BRAF V600
    |
    Erbitux (cetuximab) • Vectibix (panitumumab) • Braftovi (encorafenib) • hydroxychloroquine
    6d
    Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL (clinicaltrials.gov)
    P2, N=28, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | N=45 --> 28 | Trial completion date: Jul 2028 --> Jun 2029 | Trial primary completion date: Apr 2028 --> May 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    BRAF mutation • BRAF V600
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)
    8d
    Molecular glue degraders of HuR suppress BRAF-mutant colorectal cancer. (PubMed, Nature)
    BRAF inhibitors such as encorafenib are ineffective due to MAPK pathway reactivation driven by BRAF dimerization...dHuR abrogated BRAF expression by inducing its exon 18 skipping, and demonstrated superior suppression of BRAF-mutant CRC tumours including those gaining resistance to BRAF inhibitors. Finally, we performed kinome library CRISPR screening and revealed that inactivation of EGFR or MEK enhanced dHuR cytotoxicity, thus establishing a combinatorial strategy to treat patients with refractory BRAF-mutant CRC.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • CRBN (Cereblon)
    |
    BRAF V600E • BRAF mutation • BRAF V600
    |
    Braftovi (encorafenib)
    11d
    BEAVER: Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (clinicaltrials.gov)
    P2, N=26, Active, not recruiting, University Health Network, Toronto | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • KIAA1549
    |
    BRAF mutation • BRAF V600K • BRAF fusion
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)
    13d
    BECOME-MB: Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis (clinicaltrials.gov)
    P2, N=10, Active, not recruiting, UNICANCER | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600 • BRAF V600K
    |
    Keytruda (pembrolizumab) • Mektovi (binimetinib) • Braftovi (encorafenib)
    15d
    Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory (clinicaltrials.gov)
    P2, N=7, Active, not recruiting, Northwestern University | Recruiting --> Active, not recruiting | N=43 --> 7 | Trial primary completion date: Jul 2028 --> May 2026
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    BRAF V600E • BRAF V600
    |
    Erbitux (cetuximab) • Vectibix (panitumumab) • Braftovi (encorafenib) • hydroxychloroquine
    15d
    S2107: Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation (clinicaltrials.gov)
    P2, N=86, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2026 --> Jun 2027 | Trial primary completion date: Sep 2026 --> Feb 2026
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    BRAF V600E • BRAF V600
    |
    Opdivo (nivolumab) • Erbitux (cetuximab) • Braftovi (encorafenib) • ABP 206 (nivolumab biosimilar)
    18d
    DosinTACE: Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=48, Active, not recruiting, Nanfang Hospital, Southern Medical University | Not yet recruiting --> Active, not recruiting | Trial primary completion date: Dec 2024 --> Mar 2026
    Enrollment closed • Trial primary completion date
    |
    Tyvyt (sintilimab) • Zepsun (donafenib)
    23d
    Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory (clinicaltrials.gov)
    P2, N=43, Recruiting, Northwestern University | Trial completion date: Jul 2028 --> Jul 2030 | Trial primary completion date: Jul 2026 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    BRAF V600E • BRAF V600
    |
    Erbitux (cetuximab) • Vectibix (panitumumab) • Braftovi (encorafenib) • hydroxychloroquine
    1m
    The DoHAICs Study Expansion Phase (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Tyvyt (sintilimab) • oxaliplatin • Zepsun (donafenib)